272 results about "SCC - Squamous cell carcinoma" patented technology

The invention discloses a lung squamous cell carcinoma survival prediction method and system based on SHAP interpretability, and relates to the technical field of medical data analysis. Comprising the following steps: constructing a dynamically updated physiological feature information table based on a lung squamous cell carcinoma clinical data set of a target under multiple time nodes; and associating different survival analysis models with the physiological feature information table to predict the survival probability of the lung squamous cell carcinoma in the target body, the marginal contribution of each input feature to the output of each model is obtained by using the SHAP interpretation algorithm, and the feature uniqueness score is transparently displayed in the fusion process, so that the survival probability of the lung squamous cell carcinoma in the target body can be predicted in the actual use process. The method can visually understand how each feature affects the final prediction, and achieves automatic arbitration or manual recheck through providing a model to explain conflict measurement, invalid variable elimination and pseudo high risk verification and weighted scoring, thereby guaranteeing the reasonability and safety of prediction and intervention suggestions, reducing the decision risk, and enhancing the clinical trust.

The invention belongs to the technical field of medical image processing, and particularly relates to an esophageal cancer treatment effect and survival combined prediction method and system based on multiple modalities, and the method comprises the steps: obtaining a preoperative CT image and Hamp of an esophageal squamous cell carcinoma patient; e, the dyed digital pathological image, transcriptome data and clinical diagnosis and treatment information are preprocessed and subjected to feature extraction, and radiomics embedding representation, pathomics embedding representation and pipeline branch embedding representation are obtained respectively; the radiomics embedded representation, the pathomics embedded representation and the pipeline branch embedded representation are aligned and input into a multi-modal fusion module based on a multi-head self-attention mechanism for feature fusion, and fusion feature representation is generated; and based on the fusion feature representation, synchronously outputting a curative effect prediction result and a survival prediction result by using a multi-task output module, and evaluating model prediction performance by using a curative effect evaluation index and a survival analysis index.

The invention discloses a lung squamous cell carcinoma survival probability prediction system fusing multiple models, and relates to the technical field of medical data analysis. Comprising a data acquisition module used for acquiring a lung squamous carcinoma clinical data set and an inspection index of a patient; the data preprocessing and dynamic feature table construction module is used for preprocessing the lung squamous cell carcinoma clinical data set in existing data processing and dynamically updating a physiological feature information table; the model training and predicting module is used for carrying out training and online prediction on various survival analysis models; and the SHAP interpretation and weight calculation module is used for calling a corresponding SHAP algorithm to obtain an average absolute SHAP value of each input feature. According to the method, model interpretation conflict measurement, invalid variable elimination and pseudo high risk verification are provided, and automatic arbitration or artificial recheck is realized through weighted scoring, so that the reasonability and safety of prediction and intervention suggestions are ensured, the decision risk is reduced, and the clinical trust is enhanced.

The invention discloses a micromolecule NSD3 degradation agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a micromolecular NSD3 degradation agent, which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The small molecule NSD3 degradation agent provides a new scheme for treatment of lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

The invention discloses application of an lncRNA biomarker in esophageal squamous cell carcinoma diagnosis, and relates to the technical field of esophageal squamous cell carcinoma diagnosis. The esophageal squamous cell carcinoma marker comprises LINC00482. The lncRNA marker screened by the invention has the technical advantages of high esophageal squamous cell carcinoma diagnosis sensitivity and strong specificity, has good diagnosis characteristics, and has important significance on early diagnosis, early intervention, deep understanding of the pathological mechanism of esophageal squamous cell carcinoma and the like. In addition, the method for auxiliary diagnosis or diagnosis of esophageal squamous cell carcinoma by using the biomarker has the technical advantages of simple operation, low price and short detection period, and can meet the detection requirements of various samples such as blood, tissues and the like.

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.

The invention provides a micro-fluidic chip capable of culturing oral squamous cell carcinoma organoid and a preparation method thereof, and relates to the technical field of micro-fluidic chips, the chip comprises a four-layer structure: the first layer is a closed layer, the second layer is a culture solution / drug pool layer (containing a concentration gradient injection channel and a slow flow channel), the third layer is a matrix culture pool layer, and the fourth layer is a matrix culture pool layer. The fourth layer is a matrigel inflow layer (containing an S-shaped flow channel); the second layer and the third layer are integrally formed, and all the layers are connected through oxygen plasma welding; the problems that in the prior art, matrigel is prone to shifting, drug gradient regulation and control is poor, operation is tedious, and adaptability is insufficient are solved, the matrigel and organoids can be stably fixed, the drug concentration gradient can be precisely regulated and controlled, the nutrition supply efficiency is enhanced, the structural integration level and operation convenience are improved, and the application prospect is wide. The method is suitable for oral squamous cell carcinoma organoid culture, drug screening and tumor mechanism research.

The invention discloses a lung squamous cell carcinoma drug discovery method and system based on disturbance response scanning analysis, and belongs to the field of biological medicines.The method comprises the steps that lung squamous cell carcinoma protein expression profile data is downloaded and preprocessed, a robust network module is constructed and multi-scale analysis and evaluation are conducted, and drug genomic data are obtained based on drug genomic data. Predicting the drug sensitivity of the patient by using machine learning, and generating a DRN through difference analysis of the drug sensitivity; predicting drug-target protein binding affinity in combination with deep learning, quantifying node sensitivity through a PRS technology, calculating a DPI disturbance score and ranking drug priorities; high-ranking drugs are screened through comprehensive sensitivity analysis and literature investigation; a drug for a lung squamous carcinoma cell line is screened out through a pre-experiment and is relocated. According to the framework developed by the invention, by integrating proteomics, pharmacogenomics and dynamic network analysis, systematic analysis is provided for relocation drug identification of lung squamous cell carcinoma, and good news is brought to treatment of lung squamous cell carcinoma.

The invention provides equipment, a method and a system for evaluating prognosis of cervical cancer, squamous carcinoma and adenocarcinoma and application of the equipment, the method and the system, and belongs to the technical field of medical evaluation. Two biomarkers, namely adenylate kinase 4 and cavernous malformation 2 protein, for evaluating prognosis of cervical squamous cell carcinoma and adenocarcinoma are obtained through multivariate statistical analysis, difference screening, COX regression analysis and other biosignal analysis methods. Based on the biomarker, evaluation equipment, a computer execution method, a computer system and the like for evaluating the prognosis of cervical squamous cell carcinoma and adenocarcinoma are constructed, and the evaluation equipment, the computer execution method, the computer system and the like are used for accurately judging the prognosis condition of a cervical cancer patient.

The invention discloses a compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a compound which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The compound provided by the invention provides a new scheme for treating lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

The invention discloses an engineered bionic nucleic acid nano diagnosis and treatment agent as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims to solve the problems that an engineered macrophage membrane modified bionic nucleic acid nano diagnosis and treatment agent for oral squamous cell carcinoma is lacked in the prior art, and the curative effect on invasive tumors of the oral squamous cell carcinoma is poor. According to the engineering bionic nucleic acid nano diagnosis and treatment agent, a cationic lipid nucleic acid medicine is wrapped with a macrophage membrane, and PD1 shown as SEQ.ID.NO.1 is stably expressed on the macrophage membrane; the cationic lipid nucleic acid medicine is prepared by loading Cip2a siRNA (small interfering Ribonucleic Acid) on a cationic liposome. The bionic nucleic acid nano diagnosis and treatment agent has a huge application prospect in preparation of oral squamous cell carcinoma diagnosis kits and medicines.

The invention relates to application of recombinant humanized III-type collagen in preparation of an esophageal squamous cell carcinoma inhibitor. The invention discovers that the recombinant humanized III-type collagen can significantly inhibit the proliferation of esophageal squamous carcinoma cells and prevent the generation of malignant phenotypes of esophageal squamous carcinoma cells. Therefore, the invention can be used for preparing medicines for preventing and treating esophageal squamous carcinoma.

The invention belongs to the technical field of gene engineering, and relates to an esophageal squamous cell carcinoma diagnostic kit based on a peripheral blood mononuclear cell methylation marker and application. The kit comprises a primer pair which is used for detecting the methylation of a cg05914150 site, a cg06769875 site, a cg07475126 site, a cg08433285 site, a cg10038907 site, a cg17968322 site, a cg19572487 site, a cg20184330 site, a cg22741248 site and a cg22823192 site. According to the detection kit provided by the invention, the type of a detected sample is peripheral blood, the sample is relatively easy to obtain and non-invasive, and the patient compliance is relatively good. Abnormal methylation changes mostly exist in the early progression process of tumors, early diagnosis of ESCC can be achieved through the methylation detection method provided by the invention, and the five-year survival rate of ESCC patients is effectively increased.

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.

The invention relates to the technical field of medical image processing and intelligent grading recognition of tumors, and discloses a head and neck squamous cell carcinoma early recognition method based on radiomics and deep learning, which comprises the following steps: acquiring head and neck CT (Computed Tomography), MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) three-mode image data; a two-stage dynamic structure alignment mechanism is adopted for registration; extracting fusion radiomics features; constructing a tumor sub-feature map; outputting a tumor level and a prediction confidence coefficient through the uncertainty prediction model; and generating a saliency interpretation heat map. In the prior art, a single-mode image or a superficial layer texture feature extraction model is depended on, and especially under the condition that a heterogeneity tumor region boundary is fuzzy and different modes have significant structure offset, high-confidence accurate discrimination of a real staging state of a tumor cannot be realized. According to the method, the accuracy of early stage identification of the head and neck squamous cell carcinoma is improved by introducing the significance guide registration mechanism and the improved graph convolutional neural network and combining Dropout reasoning.

The invention relates to an mRNA (messenger Ribonucleic Acid) vaccine targeting FomA and application of the mRNA vaccine in immunotherapy of esophageal squamous carcinoma in the technical field of tumor immunotherapy. The problems that in the prior art, a specific targeting vaccine for the fusobacterium nucleatum membrane protein FomA lacks, traditional antibiotics can only kill extracellular bacteria and cannot remove intracellular colonized fusobacterium nucleatum, and cellular immunity cannot be effectively activated to remove fusobacterium nucleatum colonized in tumor tissue; the immunotherapy drug resistance of esophageal squamous carcinoma caused by fusobacterium nucleatum infection is difficult to reverse. According to the technical scheme, an mRNA molecule with a fusobacterium nucleatum FomA extracellular domain tandem repeat sequence and a lipid nanoparticle delivery system are coded, an extramembrane segment tandem repeat immune enhancement technology is adopted for design, two extracellular ring sequences are repeated for 2-5 times and connected through a connector sequence, lipid nanoparticles are composed of optimized quaternary lipids, and the lipid nanoparticles are prepared from the quaternary lipids. And a PD-1 monoclonal antibody is combined to activate FomA specific CD8 + T cell immunoreaction, so that comprehensive removal of intracellular and extracellular bacteria and bacteria targeted immune remodeling are realized.

The embodiment of the invention provides a training method of an esophageal squamous carcinoma risk prediction model, and an esophageal squamous carcinoma risk prediction method and system, and belongs to the technical field of medical treatment. According to the scheme, a training feature set is obtained, global importance analysis is carried out on the training feature set through a plurality of different feature selection algorithms, and an importance scoring result of each feature selection algorithm and consensus feature results of all the feature selection algorithms are obtained; performing screening processing according to each importance scoring result to obtain a feature subset corresponding to each feature selection algorithm; inputting each feature subset into a plurality of different classifier algorithms for training to obtain a corresponding basic model; a plurality of high-performance models are screened out from all the basic models through a multi-criterion decision classification fusion framework for weighted fusion, input features after model fusion are determined according to consensus feature results, an esophageal squamous cell carcinoma risk prediction model is obtained, the accuracy of esophageal squamous cell carcinoma risk prediction can be improved, and potential patients can be found in advance.

The invention relates to a biomarker-based near infrared spectrum characteristic wave band screening and pan cancer grading detection system and a working method thereof, and the working method comprises the following steps: a spectrum collection unit collects the near infrared spectrum of a to-be-detected plasma sample to obtain spectrum data; a spectrum abnormal value eliminating unit eliminates abnormal values; the clinical biochemical data abnormal value eliminating unit is used for eliminating abnormal values of the biochemical detection data; selecting a sample set division method and a division proportion; the spectrum pretreatment unit is used for pretreating a near infrared spectrum of a to-be-detected plasma sample; the spectral characteristic wave band screening unit screens spectral characteristic wave bands in combination with clinical biochemical indexes and near infrared spectrums, so that the accuracy of pan cancer recognition is improved; and the data analysis unit performs qualitative discriminant analysis on the near infrared spectrum data, constructs an accurate cancer primary detection model and an accurate cancer accurate detection model, preliminarily identifies cancers and finely screens esophageal squamous cell carcinoma, gastric cancer, colorectal cancer and lung cancer samples. The method has good practical application and reference value for large-scale screening of cancers.

The invention discloses application of a reagent for detecting an esophageal squamous cell carcinoma marker in preparation of an esophageal squamous cell carcinoma auxiliary diagnosis or diagnosis product, and relates to the technical field of esophageal squamous cell carcinoma diagnosis. The esophageal squamous cell carcinoma marker is selected from at least one of CST1, IBSP, HOXA11, METTL11B, PRDM13, GBX2 and TSBP1. The biomarker provided by the invention has the technical advantages of simple operation, high diagnosis sensitivity and strong specificity in auxiliary diagnosis of esophageal squamous cell carcinoma, and has good diagnosis characteristics. Compared with imaging detection, the diagnostic detection cost provided by the invention is lower, the detection period is short, the esophageal squamous cell carcinoma can be rapidly identified and diagnosed by detecting the biomarker, and the kit is suitable for large-scale clinical diagnosis of the esophageal squamous cell carcinoma in people.

The invention belongs to the technical field of biological medicine and molecular biology, and provides application of GJB6 in preparation of an esophageal squamous cell carcinoma prognosis evaluation reagent and screening of drugs for targeted treatment of esophageal squamous cell carcinoma. The low expression of the GJB6 is applied to preparation of an esophageal squamous cell carcinoma prognosis evaluation reagent. GJB6 is low in expression in ESCC patients, and ESCC prognosis is poor. And the prognosis of patients with high expression of GJB6 is better. Overexpression of GJB6 inhibits ESCC cell proliferation, migration and invasion and in-vivo tumor enlargement. The GJB6 plays a role of a cancer suppressor gene in ESCC and inhibits cell proliferation, migration and invasion. The AKT signal channel is one of downstream channels for GJB6 to regulate the occurrence and development of ESCC. The AKT inhibitor effectively inhibits GJB6 low-expression ESCC malignant phenotypes, including enhancement of cell proliferation and migration invasion ability and in-vivo tumor enlargement. The AKT is a key therapeutic target of the GJB6 low expression type ESCC.

The invention relates to the field of tumor immunotherapy, in particular to an mRNA vaccine targeting fusobacterium nucleatum membrane protein FomA and application of the mRNA vaccine in esophageal squamous cell carcinoma immunotherapy. The vaccine comprises a nucleotide sequence for coding a specific epitope of FomA, and the specific epitope contains 1-10'GGSGGGGSGG 'repetitive sequences and has homology gt in different strains; 95%. The mRNA is encapsulated in lipid nanoparticles (the particle size is 80-150 nm, the polydispersity coefficient is lt; and the liposome is composed of 38-42% of cationic lipid, 18-22% of neutral lipid, 33-37% of cholesterol and 3-5% of PEG modified lipid, and the encapsulation efficiency is 85-95%. The vaccine can specifically reduce the abundance of fusobacterium in tumors by 72.4 + / -8.0%, the tumor microenvironment is converted into an immune activation type, and the proportion of CD8 + T cells is increased from 5.2 + / -1.0% to 14.5 + / -2.0%. When the compound is combined with a PD-1 inhibitor, the objective remission rate reaches 70%, the tumor volume is reduced by 78.5 + / -8.0%, and the compound is suitable for treating clostridium-enriched esophageal squamous carcinoma.

The invention discloses an autoantibody reagent for screening early-stage lung squamous cell carcinoma. The autoantibody comprises autoantibodies of tumor-associated antigens: RNF43; or, RNF43 and KLF4; or, RNF43, KLF4, and P53; or, RNF43, KLF4, P53 and NCOR1, or, RNF43, KLF4, P53 and NCOR1; or, RNF43, KLF4, P53, NCOR1, and CCND1 are selected from the group consisting of: RNF43, KLF4, P53, the reagent provided by the invention is used for detecting the expression level of the antibody in a human body, can effectively detect the lung squamous cell carcinoma, especially early lung squamous cell carcinoma, has high sensitivity and specificity, and can enable the sensitivity to be up to 62.4% and the specificity to be up to 82.3% when the combination of RNF43, KLF4, P53, NCOR1 and CCND1 is used for diagnosing the early lung squamous cell carcinoma. Meanwhile, compared with other combinations, the Youden index is closer to 1, which shows that the combination has higher diagnostic value and higher application value.

The invention relates to the field of biomedicine, and discloses an expiration marker combination for diagnosing oral squamous cell carcinoma as well as application and a screening method of the expiration marker combination. Wherein the expiration marker combination comprises 29 oral expiration markers, a scoring model is constructed through the relative content of VOC signals of the expiration markers, the scoring model can be used for evaluating the oral squamous cell carcinoma risk of a patient, and the invention further discloses a screening method of the expiration marker combination. According to the screening method, a multi-algorithm feature union set strategy is adopted, the algorithm advantages of UTest, Boruta, LGBM, RF and the like are integrated, the limitation of a single algorithm is overcome, and the OSCC related expiration markers are recognized to the maximum extent. The core marker screening basis is clear, the PTR-TOF-MS detection process is standard, an interpretable verification mechanism is constructed, clinical popularization is facilitated, invasive biopsy dependence is reduced, diagnosis efficiency and patient compliance are improved, and important clinical and social values are achieved.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

The application discloses a kind of partition delivery environment response type hydrogel microneedle and its preparation method and application in oral squamous carcinoma treatment.The hydrogel microneedle includes backing layer and the needle tip layer being arranged on the surface of the backing layer, the needle tip layer includes multiple array distribution microneedle tip body, each the needle tip body is connected with the backing layer respectively;Wherein, the backing layer has enzyme response, and the needle tip layer has acidic pH response.The microneedle uses innovative "integration partition design", and two hydrogels with different functions are integrated in single microneedle array: backing layer responds oral flora imbalance microenvironment, needle tip layer responds tumor weak acidic microenvironment.The design can realize partition, accurate, intelligentized synergistic treatment to oral mucosa surface and deep tumor tissue, so as to overcome the technical bottleneck of traditional dosage form in space selectivity, single drug type, release behavior uncontrollable and great systemic toxicity etc.

The invention discloses a biomarker for accurate typing of esophageal squamous carcinoma lesion and application of the biomarker, and belongs to the technical field of molecular biology, the biomarker is SOX2 protein and KDM4B protein which are co-localized in nuclei, and the biomarker is applied to accurate typing of esophageal squamous carcinoma lesion with a non-diagnostic purpose. The cell proportion and distribution conditions of the SOX2 protein and the KDM4B protein are simultaneously displayed on the same section by adopting a double-label immunofluorescence method, and tests prove that the intranuclear co-localization of the SOX2 and the KDM4B can be used as an early warning mark and is used for identifying high-risk patients or early stages of precancerous lesions or distinguishing tumor patients, so that the missed diagnosis rate is reduced, and the diagnosis time is shortened. Therefore, a reliable basis is provided for accurate typing of esophageal squamous carcinoma lesions.

The invention relates to the technical field of biological medicine, and relates to a polypeptide in targeted combination with SOX2 protein and application thereof, the polypeptide has an amino acid sequence as shown in SEQ ID NO.1, or has at least 85%, 90%, 95% or more than 99% of sequence identity with the amino acid sequence; the polypeptide inhibits phase separation of SOX2, liquid drops formed by phase separation of SOX2 can be avoided, then the situation that the liquid drops wrap chemotherapeutic drugs, influence the curative effect of the chemotherapeutic drugs and cause tolerance of tumor cells to the chemotherapeutic drugs is avoided, and the polypeptide does not influence the transcription activation function of SOX2 serving as a transcription factor; the polypeptide can inhibit the phase separation of the SOX2, so that the regulation of normal physiological functions, such as high expression in organs such as eyes of a human body, of the SOX2 as a transcription factor is not influenced, and therefore, the polypeptide disclosed by the invention can reverse chemotherapy drug resistance of tumors such as squamous carcinoma by inhibiting the phase separation of the SOX2, can be used for adjuvant therapy of the tumors such as squamous carcinoma, and has no obvious toxic or side effect on each organ of an organism.

The application discloses a biomarker combination and application thereof in evaluation of chemoradiotherapy efficacy of esophageal squamous cell carcinoma. The biomarker combination comprises STOX2, TENM4, AC069277.1, B4GALNT3, CASC15, PPFIA1, NTN4, RDH10, CYYR1 and RNF165. The application performs niche analysis on samples through spatial transcriptome data, identifies an immune niche, and then screens the above-mentioned biomarker combination related to chemoradiotherapy efficacy, and a scoring model for evaluating chemoradiotherapy efficacy of esophageal squamous cell carcinoma is constructed based on the biomarker combination. The scoring model has high prediction accuracy and clinical applicability, provides a new tool for objective evaluation of chemoradiotherapy efficacy of esophageal squamous cell carcinoma, and has significant clinical transformation potential and application value.

The invention provides an application of ginkgetin in enhancing VS4718 or ponatinib in resisting the progress of esophageal squamous cell carcinoma. It is found that ginkgo biflavone can enhance the growth and invasion inhibition effect of VS4718 or ponatinib on esophageal squamous carcinoma cells; ginkgo biflavone is used for enhancing the inhibition effect of VS4718 or ponatinib on glycolipid metabolism of tumor cells, and the ginkgo biflavone is respectively combined with VS4718 or ponatinib to generate a synergistic anti-cancer effect.

The invention discloses a novel fusobacterium strain Fusobacteria sp.HPSCC05 and an application of the novel fusobacterium strain Fusobacteria sp.HPSCC05. The preservation number of the novel fusobacterium strain Fusobacteria sp.HPSCC05 is CCTCC (China Center For Type Culture Collection) NO: M2025588. According to the invention, Fusobacterium sp.HPSCC05 derived from hypopharyngeal squamous cell carcinoma tissues is successfully separated, the strain has key technical attributes of stable growth, repeatable culture, clear preservation conditions and the like, and the problem of deficiency of current hypopharyngeal carcinoma related strains is solved. Fusobacteria sp.HPSCC05 is identified as a new fusobacterium species, and the blank of hypopharyngeal carcinoma tumor ecological niche specific strain resources is filled up. The method comprises the following steps: establishing an in-vitro verification model (fusobacterium-hypopharyngeal squamous carcinoma cell co-culture model) of the hypopharyngeal carcinoma promoting effect of the Fusobacterium sp.HPSCC05, and providing a replicable culture mode;